Factors influencing outcomes in patients with Eisenmenger syndrome: a nine-year follow-up study

Imagem de Miniatura
Arquivos
art_CLAVE_Factors_influencing_outcomes_in_patients_with_Eisenmenger_syndrome_2017.PDF (233.43 KB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SAGE PUBLICATIONS INC
Autores
MAEDA, Nair Y.
Citação
PULMONARY CIRCULATION, v.7, n.3, p.635-642, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
In patients with Eisenmenger syndrome, life expectancy is usually longer than in patients with other forms of pulmonary arterial hypertension (PAH). We conducted a cohort study in which patients were followed over a long period of time in an attempt to identify potential predictors of clinical outcomes. Sixty-seven treatment-naive patients were enrolled (age range = 12-60 years; median age = 33 years). Baseline demographic, diagnostic, and functional parameters, plasma levels of endothelial dysfunction markers, and treatment-related data were tested for possible correlations with event-free survival. Patients were started on oral PAH drugs at the beginning of follow-up (n = 23), during follow-up (n = 33), or remained untreated (n = 11). The duration of follow-up was 0.54-9.89 years (median = 7.13 years), with an overall survival rate of 82% and an event-free survival rate of 70%. The estimated mean for event-free survival time was 7.71 years (95% confidence interval [CI] = 6.86-8.55 years). Of the 16 variables that were analyzed, the duration of exposure to PAH drugs was identified as an independent protective factor (hazard ratio [HR] = 0.25 for quartiles, 95% CI = 0.14-0.47, P < 0.001). The initial functional class (HR = 3.07; 95% CI = 1.01-9.34; P = 0.048), the severity of right ventricular dysfunction (HR = 2.51 [mild, moderate or severe dysfunction]; 95% CI = 1.22-5.19; P = 0.013) and plasma von Willebrand factor concentration (HR = 1.74 for quartiles; 95% CI = 1.07-2.83; P = 0.026) were identified as risk factors. The length of exposure to oral PAH therapies influences survival favorably in Eisenmenger patients. This may be of interest for communities where access to medications is restricted.
Palavras-chave
pulmonary hypertension, Eisenmenger syndrome, von Willebrand factor, survival, congenital heart disease
URI
https://observatorio.fm.usp.br/handle/OPI/21801
Referências
  1. Barreto AC, 2008, BRAZ J MED BIOL RES, V41, P657
  2. Barst RJ, 2014, AM J CARDIOL, V113, P147, DOI 10.1016/j.amjcard.2013.09.032
  3. Brun H, 2009, CONGENIT HEART DIS, V4, P153, DOI 10.1111/j.1747-0803.2009.00297.x
  4. D'Alto M, 2014, HEART, V100, P1322, DOI 10.1136/heartjnl-2014-305574
  5. D'Alto M, 2012, EUR RESPIR REV, V21, P328, DOI 10.1183/09059180.00004712
  6. Damas JK, 2004, CIRCULATION, V110, P999, DOI 10.1161/01.CIR.0000139859.68513.FC
  7. Diller GP, 2006, EUR HEART J, V27, P1737, DOI 10.1093/eurheartj/ehl116
  8. Diller GP, 2012, HEART, V98, P736, DOI 10.1136/heartjnl-2011-301522
  9. Dimopoulos K, 2014, EUR HEART J, V35, P691, DOI 10.1093/eurheartj/eht437
  10. Dimopoulos K, 2010, CIRCULATION, V121, P20, DOI 10.1161/CIRCULATIONAHA.109.883876
  11. Galie N, 2006, CIRCULATION, V114, P48, DOI 10.1161/CIRCULATIONAHA.106.630715
  12. Hopkins WE, 1996, J HEART LUNG TRANSPL, V15, P100
  13. Jensen AS, 2015, CIRC-CARDIOVASC IMAG, V8
  14. Kaemmerer H, 2010, CURR CARDIOL REV, V6, P343, DOI 10.2174/157340310793566154
  15. Kawut SM, 2005, CHEST, V128, P2355, DOI 10.1378/chest.128.4.2355
  16. KIDD L, 1993, CIRCULATION, V87, P38
  17. Lang RM, 2015, J AM SOC ECHOCARDIOG, V28, P1, DOI 10.1016/j.echo.2014.10.003
  18. Lopes AA, 2011, BRAZ J MED BIOL RES, V44, P1269, DOI 10.1590/S0100-879X2011007500149
  19. Lopes AA, 2000, AM HEART J, V139, P618, DOI 10.1016/S0002-8703(00)90038-3
  20. Lopes AA, 2010, CHEST, V137, p78S, DOI 10.1378/chest.09-2960
  21. Manes A, 2014, EUR HEART J, V35, P716, DOI 10.1093/eurheartj/eht072
  22. Mebus S, 2010, CURR CARDIOL REV, V6, P356, DOI 10.2174/157340310793566163
  23. Moceri P, 2012, CIRCULATION, V126, P1461, DOI 10.1161/CIRCULATIONAHA.112.091421
  24. Reardon LC, 2012, AM J CARDIOL, V110, P1523, DOI 10.1016/j.amjcard.2012.06.061
  25. Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010
  26. SAHA A, 1994, INT J CARDIOL, V45, P199, DOI 10.1016/0167-5273(94)90166-X
  27. Sakamaki F, 2000, CIRCULATION, V102, P2720
  28. Shitrit D, 2002, CHEST, V122, P1674, DOI 10.1378/chest.122.5.1674
  29. Simonneau G, 2013, J AM COLL CARDIOL, V62, pD34, DOI 10.1016/j.jacc.2013.10.029
  30. Smadja DM, 2009, CIRCULATION, V119, P374, DOI 10.1161/CIRCULATIONAHA.108.808246
  31. Van De Bruaene A, 2011, EUR HEART J, V32, P2790, DOI 10.1093/eurheartj/ehr130

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03